Snake Cathelicidin from Bungarus fasciatus Is a Potent Peptide Antibiotics

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

Citation

Published Version
doi:10.1371/journal.pone.0003217

Citable link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:5347480

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Snake Cathelicidin from *Bungarus fasciatus* Is a Potent Peptide Antibiotics

Yipeng Wang\(^1,4\), Jing Hong\(^2,4\), Xiuhong Liu\(^3,9\), Hailong Yang\(^1,4\), Rui Liu\(^3\), Jing Wu\(^1,4\), Aili Wang\(^3\), Donghai Lin\(^2\), Ren Li\(^1,3,9\)

\(^1\)Biotoxin Units of Key Laboratory of Animal Models and Human Disease Mechanisms, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan, China, \(^2\)Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China, \(^3\)Key Laboratory of Microbiological Engineering of Agricultural Environment, Ministry of Agriculture, Life Sciences College of Nanjing Agricultural University, Nanjing, Jiangsu, China, \(^4\)Graduate School of the Chinese Academy of Sciences, Beijing, China

### Abstract

**Background:** Cathelicidins are a family of antimicrobial peptides acting as multifunctional effector molecules of innate immunity, which are firstly found in mammals. Recently, several cathelicidins have also been found from chickens and fishes. No cathelicidins from other non-mammalian vertebrates have been reported.

**Principal Findings:** In this work, a cathelicidin-like antimicrobial peptide named cathelicidin-BF has been purified from the snake venoms of *Bungarus fasciatus* and its cDNA sequence was cloned from the cDNA library, which confirm the presence of cathelicidin in reptiles. As other cathelicidins, the precursor of cathelicidin-BF has cathelin-like domain at the N terminus and carry the mature cathelicidin-BF at the C terminus, but it has an atypical acidic fragment insertion between the cathelin-like domain and the C-terminus. The acidic fragment is similar to acidic domains of amphibian antimicrobial precursors. Phylogenetic analysis revealed that the snake cathelicidin had the nearest evolution relationship with platypus cathelicin. The secondary structure of cathelicidin-BF investigated by CD and NMR spectroscopy in the presence of the helicogenic solvent TFE is an amphipathic \(\alpha\)-helical conformation as many other cathelicidins. The antimicrobial activities of cathelicidin BF against forty strains of microorganisms were tested. Cathelicidin-BF efficiently killed bacteria and some fungal species like domain and the C-terminus. The acidic fragment is similar to acidic domains of amphibian antimicrobial precursors. Phylogenetic analysis revealed that the snake cathelicidin had the nearest evolution relationship with platypus cathelicin. The secondary structure of cathelicidin-BF investigated by CD and NMR spectroscopy in the presence of the helicogenic solvent TFE is an amphipathic \(\alpha\)-helical conformation as many other cathelicidins. The antimicrobial activities of cathelicidin BF against forty strains of microorganisms were tested. Cathelicidin-BF efficiently killed bacteria and some fungal species.

**Conclusion:** Discovery of snake cathelicidin with atypical structural and functional characterization offers new insights on the evolution of cathelicidins. Potent, broad spectrum, salt-independent antimicrobial activities make cathelicidin-BF an excellent candidate for clinical or agricultural antibiotics.

---

### Introduction

Innate immunity uses gene-encoded antimicrobial peptides to form a first line of host defense against noxious microorganisms [1,2]. A large amount of antimicrobial peptides have been identified from animals, plants and microorganisms. Several families of antimicrobial peptides including cathelicidin, liver-expressed antimicrobial peptide (LEAP) or hepcidin, histatin, and defensin have been identified from mammals [3–7]. Defensins and hepcidins are characterized by the presence of multiple disulfide bridges, whereas histatins and most of cathelicidins are linear molecules without disulfide bridges.

After the first discovery of cathelicidin (Bac5) from bovine neutrophils, a large amount of cathelicidins have been identified from other mammalians [8–13]. As other antimicrobial peptide families, structurally divergent cathelicidins have been found, even in a single mammalian species. For example, there are at least seven cathelicidins in cattle, horse, pig, sheep, and goat [8]. Some exceptions are in human, rhesus monkey, mouse, rat, and guinea pig, only a single cathelicidin was found [8,14–18].

Cathelicidin antimicrobial peptides are released from their corresponding inactive precursors by proteolytic cleavage [8]. The cathelicidin family of proteins is characterized by the presence of a highly conserved anionic cathelin domain [3,8,19]. Cathelin is an inhibitor of the cysteine proteinase cathepsin L [20]. In the precursors of cathelicidins, the highly conserved cathelin domains composed of about 100 amino acid residues is flanked by a signal peptide fragment (approximately 30 residues long) on its N-terminus, and by a structurally divergent cationic antimicrobial peptide region on its C-terminus [8]. Upon activation, most of cathelicidin precursors proteolytically cleaved to release the cathelin domain and the C-terminal mature antimicrobial.
peptides. Some intact cathelicidin precursors are also found in the
biological fluids where cathelicidin expressed [3,21]. Elastase seems to be the most common peptidase to release mature

cathelicidins [22,23]. In human hCAP18, however, protease-3

cleaves the proprotein [24]. Mature cathelicidins can be further
degraded by some serine proteases because multiple cationic

amino acid residues (Arg or Lys) are in the sequences of

cathelicidins [25]. In addition, hCAP18 could be degraded by

aspartyl protease (gastric) at vaginal pH. Some hydrolytic

fragments of cathelicidin were found to possess increased

antimicrobial abilities [26].

Recently, several cathelicidins have been identified from some

non-mammalian vertebrates including hagfish [27], rainbow trout

[28,29], Atlantic salmon [29], and chicken [30,31]. As the oldest

jawless craniates, hagfish lacks adaptive immunity [8,32]. The

presence of cathelicidins in hagfish may indicate that cathelicidin
genes appeared early in phylogenesis [8]. Cathelicidins have been

found from most of vertebrates including fish, bird, mammalian,

whereas no cathelicidins have been found from amphibians and

reptiles. In this work, a cathelicidin from snake was identified and

characterized.

Materials and Methods

Materials

B. fasciatus crude venom and venomous glands were collected from

Guang Xi Province, China. The SMART™ PCR cDNA

synthesis kit was purchased from Clontech, USA. Chromatogra-

phy media Sephadex G-50 and CM-Sephadex C-25 were

obtained from Amersham Bioscience, Sweden. Trifluoroacetic

acid (TFA, HPLC grade) was from Perkin-Elmer. Acetonitrile

obtained from Amersham Bioscience, Sweden. Trifluoroacetic

acid synthesis kit was purchased from Clontech, USA. Chromatogra-

phy (RP-HPLC) C4 column (30 cm

0.46 cm) was

collected and finally purified by reverse phase high performance

liquid chromatography (RP-HPLC) C4 column (30 cm×0.46 cm) was

from Agilent. The pMD18-T vector was from Takara, Dalian,

China. All other reagents were of analytical or sequencing grade.

The animals used for the experiments were treated according to

the protocols evaluated and approved by the ethical committee of

Kunming Institute of Zoology.

Isolation of cathelicidin-BF

The purification procedure was according to our previously

reported technique, from the venom of B. fasciatus crude venom was first fractionated using gel filtration chromatography Sephadex G-50 column (26 cm×100 cm), equilibrated with 50 mM Tris–HCl, 50 mM NaCl (pH 7.8). The elution was performed with the same buffer and monitored at UV absorption of 280 nm. The peak having antimicrobial activity was collected and further dialyzed against PBS (pH 6.0). The dialyzed product was next subjected to the cation-exchange CM-Sephadex C-25 column (1.6 cm×30 cm). The elution was achieved with a linear NaCl gradient, at a flow rate of 1 ml/min. The peak with antimicrobial activity was collected and finally purified by reverse phase high performance liquid chromatography (C4), equilibrated with 0.1% (v/v) TFA/ water. The elution was performed with a linear gradient of

acetonitrile at a flow rate of 0.7 ml/min.

Primary structural analysis

The amino acid sequence of the N-terminus was determined by the

automated Edman degradation using an Applied Biosystems

cycled liquid-phase sequencer, model 491. Electrospray ionization

mass spectrometry (ESI-MS) was used to determine the molecular

weight by a Finnigan LCQ ion trap mass spectrometer (Thermo-

Finnigan, San Jose, CA, USA) in positive-ion mode. The sample

solutions (50%H2O/50%ACN) were infused into the mass

spectrometer via a Harvard syringe pump (Holliston, MA, USA). The spray voltage was set to +4.5 kV. Spectra were

acquired by summing 30 scans.

CD and NMR spectroscopy

Circular dichroism (CD) spectra were recorded at 298 K on a

JASCO J-410 spectrometer (Jasco, Japan). Samples were prepared

by dissolving the peptide powder to a concentration of 90 µM in

TFE/H2O mixtures or in SDS micelles of different concentrations.
The spectra were measured between 190 and 250 nm using 0.1 cm

path-length cell with 1 nm bandwidth, 1 sec response time, and a

scan speed of 100 nm/min. Three consecutive scans per sample

were performed, added and averaged followed by subtraction of the

signal of the solvent. The secondary structure elements of the

peptides were estimated according to the Yang formula [35].

Samples for nuclear magnetic resonance (NMR) measurements

contained 4 mM cantheicidin-BF in TFE-d3/H2O (9:1, v/v) at

pH 6.5, or in 300 mM SDS-d25 at pH 6.5. All NMR spectra were

recorded at 298 K on a Varian Unity INOVA 600 MHz

spectrometer equipped with three RF channels and a triple

resonance z-axis pulsed-field gradient probe. The 2D 1H-1H

TOCSY spectra were acquired with a mixing time of 75 ms, while

1H-1H NOESY spectra were acquired with mixing times of 200

and 300 ms. The watergate approach was employed for water

suppression. Data were collected with 256 and 1024 complex data

points in t1 and t2 dimensions, respectively. Signals were averaged

over 64 transients. All NMR spectra were processed and analyzed

using the NMRPipe/NMRDraw software and the Sparky

program [36,37]. Linear prediction in the t1 dimension was used

before the Fourier transformation. Assignments of the proton

resonances were achieved using both TOCSY and NOESY

spectra. The 1H chemical shifts were referenced to TSP. The

secondary structure was predicted using the Hα Chemical Shift

Index approach [38].

SMART cDNA synthesis

Total RNA was extracted using TRizol (Life Technologies, Ltd.)

from the venomous glands of B. fasciatus. cDNA was synthesized by

SMART™ techniques by using a SMART™ PCR cDNA synthesis

kit (Clontech, Palo Alto, CA). The first strand was synthesized by

using cDNA 3’ SMART CDS Primer II A, 5’-AAGCAGTGG-TATGAAGCAGAGTACT (30) N-1N-3

and 300 ms. The watergate approach was employed for water

suppression. Data were collected with 256 and 1024 complex data

points in t1 and t2 dimensions, respectively. Signals were averaged

over 64 transients. All NMR spectra were processed and analyzed

using the NMRPipe/NMRDraw software and the Sparky

program [36,37]. Linear prediction in the t1 dimension was used

before the Fourier transformation. Assignments of the proton

resonances were achieved using both TOCSY and NOESY

spectra. The 1H chemical shifts were referenced to TSP. The

secondary structure was predicted using the Hα Chemical Shift

Index approach [38].

SMART cDNA synthesis

Total RNA was extracted using TRizol (Life Technologies, Ltd.)

from the venomous glands of B. fasciatus. cDNA was synthesized by

SMART™ techniques by using a SMART™ PCR cDNA synthesis

kit (Clontech, Palo Alto, CA). The first strand was synthesized by

using cDNA 3’, SMART CDS Primer II A, 5’-AAGCAGTGG-TATGAAGCAGAGTACT (30) N-1N-3’

N=A, C, G or T; N-

AAGCAGTGG-3

and 300 ms. The watergate approach was employed for water

suppression. Data were collected with 256 and 1024 complex data

points in t1 and t2 dimensions, respectively. Signals were averaged

over 64 transients. All NMR spectra were processed and analyzed

using the NMRPipe/NMRDraw software and the Sparky

program [36,37]. Linear prediction in the t1 dimension was used

before the Fourier transformation. Assignments of the proton

resonances were achieved using both TOCSY and NOESY

spectra. The 1H chemical shifts were referenced to TSP. The

secondary structure was predicted using the Hα Chemical Shift

Index approach [38].

SMART cDNA synthesis

Total RNA was extracted using TRizol (Life Technologies, Ltd.)

from the venomous glands of B. fasciatus. cDNA was synthesized by

SMART™ techniques by using a SMART™ PCR cDNA synthesis

kit (Clontech, Palo Alto, CA). The first strand was synthesized by

using cDNA 3’, SMART CDS Primer II A, 5’-AAGCAGTGG-TATGAAGCAGAGTACT (30) N-1N-3’

N=A, C, G or T; N-

AAGCAGTGG-3

and 300 ms. The watergate approach was employed for water

suppression. Data were collected with 256 and 1024 complex data

points in t1 and t2 dimensions, respectively. Signals were averaged

over 64 transients. All NMR spectra were processed and analyzed

using the NMRPipe/NMRDraw software and the Sparky

program [36,37]. Linear prediction in the t1 dimension was used

before the Fourier transformation. Assignments of the proton

resonances were achieved using both TOCSY and NOESY

spectra. The 1H chemical shifts were referenced to TSP. The

secondary structure was predicted using the Hα Chemical Shift

Index approach [38].

SMART cDNA synthesis

Total RNA was extracted using TRizol (Life Technologies, Ltd.)

from the venomous glands of B. fasciatus. cDNA was synthesized by

SMART™ techniques by using a SMART™ PCR cDNA synthesis

kit (Clontech, Palo Alto, CA). The first strand was synthesized by

using cDNA 3’, SMART CDS Primer II A, 5’-AAGCAGTGG-TATGAAGCAGAGTACT (30) N-1N-3’

N=A, C, G or T; N-

AAGCAGTGG-3

and 300 ms. The watergate approach was employed for water

suppression. Data were collected with 256 and 1024 complex data

points in t1 and t2 dimensions, respectively. Signals were averaged

over 64 transients. All NMR spectra were processed and analyzed

using the NMRPipe/NMRDraw software and the Sparky

program [36,37]. Linear prediction in the t1 dimension was used

before the Fourier transformation. Assignments of the proton

resonances were achieved using both TOCSY and NOESY

spectra. The 1H chemical shifts were referenced to TSP. The

secondary structure was predicted using the Hα Chemical Shift

Index approach [38].
DNA sequencing was performed on an Applied Biosystems DNA sequencer, model ABI PRISM 377.

Expression profile of tissues
Reverse transcription-polymerase chain reaction (RT-PCR) was carried out to analyze gene expression of cathelicidin-BF in *B. fasciatus*. Total RNA extraction from different tissues and first-strand cDNA synthesis were the same as described above. The primers were, forward primer, 5′-cathelicidin: 5′-ATGGAAGGTTCTTCTTGGAA AGACC-3′, and reverse primer, 3′-cathelicidin: 5′-CAATTAGAGGGATGGA ACC-3′. PCR conditions were: 95°C (3 min), and 30 cycles of 95°C (30 s), 56°C (30 s), 72°C (3 min) followed by a 15 min extension period at 72°C. The control PCR was performed using the specific primers (forward primer, actin-s 5′-GGGTGTGATGGT TGGCATGG-3′, and reverse primer, actin-as 5′-CAAATTAGAAGGGGATGGAG ACC-3′) for snake actin, using the same conditions as above.

Alignment and phylogenetic comparison of cathelicidins
Cathelicidin sequences were obtained from the protein database at the National Center for Biotechnology Information. The phylogenetic tree is constructed by neighbor-joining analysis, using the ClustalW program (version 1.8).

Antimicrobial testing
Antimicrobial activities of cathelicidin-BF and cathelicidin-BF15 (VKRFKKFFRKLLKKSV) were tested according to our previous methods [39–42]. Ampicillin, benzylpenicillin (Amresco) and Imipenem and Gilastatin Sodium for Injection (ICS, Merck) were used as positive controls. The details were provided in the Materials and Methods S1.

Bacteria killing kinetics
In vitro bacteria killing kinetics of cathelicidin-BF, ICS (its minimal inhibitory concentration [MIC] for *Escherichia coli* 08A866 is 0.15 μg/ml), and HDW (an antimicrobial peptide from the frog of *Rana nigrovittata*, with a amino acid sequence of FIGPVLKAT-SILPTAIKFKCC, its MIC for *E. coli* 08A866 is 18.7 μg/ml), respectively, were determined according to the methods described by Mygind *et al* [43]. The details were provided in the Materials and Methods S1.

Hemolysis, cytotoxicity, serum stability
Hemolytic activity was checked by incubating the tested samples with human red blood cells to determine hemoglobin releasing ability by measuring the absorbance at 540 nm, using 1% Triton X-100 as a positive control. Cytotoxicity and serum stability were

Figure 1. The cDNA sequence encoding cathelicidin-BF and the predicted precursor amino acid sequence. The amino sequence of purified cathelicidin-BF is boxed. The stop codon is indicated by a star (*). The potential polyadenlation signal (AATAAA) is underlined.
doi:10.1371/journal.pone.0003217.g001
measured according the methods described by Mygind et al [43]. The details were provided in the Materials and Methods S1.

Synthetic Peptides

All of the peptides used for the bioactivity assays and NMR analysis in this paper were synthesized by the peptide synthesizer (433A, Applied Biosystems) in AC SCIENTIFIC (Xi An) INC. (Xi An, China) and analyzed by HPLC and MALDI-TOF mass spectrometry to confirm that the purity was higher than 95%. All peptides were dissolved in water.

Results

Isolation of cathelicidin-BF from the snake venoms of B. fasciatus

The crude snake venom was separated into four fractions by Sephadex G-50 gel filtration as our previous report (Figure S1a) (Fig. S1a) [33,34]. The fraction III, containing antimicrobial activity was further subject to CM-Sephadex C-25 cation-exchange column, and nine sub-fractions were collected (Figure S1b). The fraction VI with both trypsin-inhibitory and antimicrobial activities was further purified using RP-HPLC. The peak with antimicrobial activity is marked with an arrow in Figure S1c. The purified antimicrobial peptide was named cathelicidin-BF. The molecular mass and purity of purified cathelicidin-BF was further analyzed by a ESI mass spectrometry, giving a \([\text{M} + 7\text{H}]^+ = 521.1, 607.6, 729.1\) and \([\text{M} + 17\text{H}]^+ = 991.5\) (Figure S2), indicating that purified cathelicidin-BF has a molecular weight of 3637.5–3638.5.

Structure characterization of cathelicidin-BF

Purified cathelicidin-BF was subjected to amino acid sequence analysis using automated Edman degradation. Its amino acid sequence is KFFRKLKKSVKKRAKEFFKKPRVIGVSIPF. Cathelicidin-BF is composed of 30 amino acid residues including 12 basic residues (9 Lys and 2 Arg), 5 phenylalanines, and only one acidic amino acid residue (Glu). It is a lysine-rich and phenylalanine-rich peptide. Analysis using the ExPASy MW/pl tool (http://www.expasy.ch/tools/pl_tool.html) showed that cathelicidin-BF had the predicted pl (isoelectric point) of 11.79 and a predicted molecular weight of 3637.5 that matched well with the observed mass by ESI mass spectrometry (Figure S2). By BLAST search, no similar sequence was found in GenBank.

Several positive clones, which contained an insert of 750 bp were identified and isolated from B. fasciatus venomous gland cDNA library. The complete nucleotide sequence of cDNA (GenBank accession EU753183) and deduced amino acid sequence of cathelicidin-BF precursor are shown in Figure 1. Unexpectedly, the cathelicidin-BF precursor displays the maximal similarity (47%) with predicted myeloid cathelicidin 3 from Ornithorhynchus anatinus (GenBank accession XP_001512130) by BLAST search. The protein precursor is composed of 191 amino acid (aa) residues, including a predicted signal peptide, a conserved cathelin domain and a mature cathelicidin-BF. Noticeably, four cysteines that are conserved in the cathelin domain of all mammalian cathelicidins are also invariantly spaced in cathelicidin-BF precursor, suggesting that the snake cathelicidin-BF precursor is a real mammalian cathelicidin.

The amino acid sequence of cathelicidin-BF determined by Edman degradation is identical with the amino acid sequence deduced from the cDNA sequence. There is a possible cleavage site (Valine157) for elastase at the N-terminus of the mature cathelicidin-BF (Figure 1). Based on the possible cleavage site, a 34-aa peptide should be released from the precursor, but the purified cathelicidin-BF is only composed of 30 aa. Different from other cathelicidins, there is an acidic domain between the cathelin domain and the antimicrobial peptide in the cathelicidin-BF precursor (Figure 2).

![Figure 2. Multiple sequence alignment of snake cathelicidin with other representative cathelicidins.](doi:10.1371/journal.pone.0003217.g002)
Evolution analysis revealed that all vertebrate cathelicidins formed three distinct clusters with fish cathelicidins located in a separated clade from others. Supported by a bootstrap value of 77%, cathelicidin-BF was clustered with platypus CATH-3 (Figure 3). Although platypus is a mammal, it also has reptilian features. For instance, it lays eggs and it is venomous [44]. The close evolution relationship of cathelicidin-BF found in the venom of B. fasciatus with platypus cathelicidins may provide further proof for platypus’s reptilian features.

Secondary structures detected by CD and NMR
The secondary structure elements in different solvent environments were detected by CD spectroscopy (Figure S3, Table S1). In H$_2$O, the CD spectrum of cathelicidin-BF showed a strong negative band at 200 nm, indicative of a random-coil conformation. Interestingly, in TFE/H$_2$O mixtures, the CD spectra showed double minima at 208 and 222 nm, indicating a highly α-helical conformation. The signals at 208 and 222 nm were intensified gradually by increasing concentrations of TFE, which indicated that the helicity of the peptide was increased in more hydrophobic or membrane-mimetic environments. The CD spectra of the peptide in SDS micelles also showed a typical α-helix pattern and the content of the α-helix structure increased with the increasing SDS concentration.

NMR spectra recorded on the peptide in SDS micelles were of low quality and cannot be used for structural analysis, due to aggregation of the peptide in negative charged SDS micelles. Therefore, the helical structure of the peptide in TFE/H$_2$O mixture was investigated using NMR spectroscopy. Table S2 lists the nearly complete assignments of the proton chemical shifts of cantheicidin-BF in TFE/H$_2$O mixture (9:1, v/v). Comparison of the H-N-HN region of NOESY spectrum recorded on cantheicidin-BF in H$_2$O with that in TFE/H$_2$O (9:1, v/v) illustrates that, the peptide adopts a stable secondary structure in TFE/H$_2$O mixture (Figure S4). The H$_\alpha$ CSI prediction is indicative of a helical structure in the N-terminal region comprising residues F2–F18 (Figure S5), although a well-defined three-dimensional structure of the peptide in TFE/H$_2$O mixture has not been obtained yet, mainly due to the deficiency of enough unambiguous conformational restraints for the exact structural analysis.

The amphipathic helical conformation is well known to be a crucial factor for many antimicrobial peptides to interact with membranes [45,46]. On basis of the rough structural analysis described above, it is indicated that the N-terminal region of cantheicidin-BF adopts a typical amphipathic α-helical conformation (Figure S6) as many other cantheicidins.

Expression profile of tissues
Using actin as control, expression pattern of cathelicidin-BF was investigated by RT-PCR. Tissue distribution of cathelicidin-BF expression in snake tissues were illustrated in Fig. 4. All the selected tissues including stomach, trachea, skin, muscle, heart, kidney, lung, brain, intestine, spleen, liver, ovary and venomous gland can express this protein.

Antimicrobial activities
As listed in Table 1, cathelicidin-BF and its analogue, cathelicidin-BF15 showed strong antimicrobial activities against tested microorganisms. Of the 40 tested microorganism strains, cathelicidin-BF exerted potent antimicrobial ability against most of Gram-negative bacteria (either standard strains or clinically isolated drug-resistance strains). For most of _E. coli_, the MICs are lower than 2.3 μg/ml, while ampicillin, benzylpenicillin and ICS are effective only to standard strain with a MIC of 18.7, 57.5 and 0.15 μg/ml respectively. The lowest MIC for _K. pneumoniae_ is 0.3 μg/ml, while ampicillin, benzylpenicillin and ICS are effective only to standard strain with a MIC of 150, 18.7 and 9.4 μg/ml respectively. In contrast, most of _S. aureus_ are not so sensitive for cathelicidin-BF, only one strain could be killed by cathelicidin-BF.
with a low MIC (4.7 μg/ml). Another Gram-positive bacteria genus, *Bacillus* also seems to be sensitive for cathelicidin-BF and cathelicidin-BF15. A dangerous clinically isolated strain, *Salmonella typhi* could also be killed by cathelicidin-BF and cathelicidin-BF15 with a low MIC (1.2 μg/ml). Cathelicidin-BF and cathelicidin-BF15 are the same effective to some fungi as bacteria, for example, *C. albicans* ATCC2002 (with a MIC of 4.7 μg/ml), and *P. pastoris* (with a MIC of 0.3 μg/ml). Cathelicidin-BF exerted obvious antimicrobial activity against some saprophytic fungus such as *A. terreus* GIM3.34 (with a MIC of 18.7 μg/ml), *A. niculans* (with a MIC of 4.7 μg/ml), and *C. globosum* (with a MIC of 37.5 μg/ml).

All the tested classic antibiotics including Ampicillin, Benzylpenicillin and ICS had no effect on these funguses. Several other cathelicidin-BF analogues, KF1–11 (KFFRKLKKSVK), KF12–19 (KRAKEFFK) and KF20–30 (KPRVIGVSIPF) had no any antimicrobial activity.

The antimicrobial activity of cathelicidin-BF in different solutions was also investigated as listed in Table 2. In 150 mM phosphate buffer solution (PBS) and 150 mM NaCl solution, cathelicidin-BF had stronger antimicrobial activities than in water. It suggested that salts could increase cathelicidin-BF's antimicrobial ability.

Bacteria killing kinetics

Using the antibiotics ICS as a positive control, antibacterial properties of the snake cathelicidin-BF were tested by the colony counting assay. As listed in Table 3 and Table 4, cathelicidin-BF could rapidly exert its antibacterial activities. It just took less than 1 minute to kill all the *E. coli* at the concentration of 1, 5 or 10 times of MIC. The antibacterial activity was proved to be lethal for *E. coli*. *E. coli* was not capable of resuming growth on agar plates after a 6-h treatment with concentrations above the corresponding MICs. In contrast, the antibiotics, ICS could not clean the bacteria within 6 h at the concentration of 1 or 5 times of MIC. Only 10 times MIC of ICS could clean all the *E. coli* within 6 h. Furthermore, *E. coli* treated by 1 time MIC of ICS was capable of resuming growth during 6 h.

In order to compare properties with other antimicrobial peptide, the frog antimicrobial peptide HDW was used as a control. Their bacteria killing kinetics during 30 min was listed in Table 4. Although HDW had a rapid bacteria killing ability, cathelicidin-BF is faster to clean *E. coli* than HDW. Cathelicidin-BF just took less than 1 minute to clean *E. coli*, while HDW took several minutes.

Hemolysis, cytotoxicity, serum stability

Cathelicidin-BF had little hemolytic activity on human red blood cells even with peptide concentrations up to 400 μg/ml. At the same concentration, cathelicidin-BF was neither cytotoxic for mouse macrophage (RAW264.7) nor for human liver tumor cell (HepG2) (data not shown). Thus, it showed considerable selectivity for microorganisms over mammalian cells *in vitro*.

Serum stability was checked by incubating 100 μg/ml cathelicidin-BF and cathelicidin-BF15 with 90% fresh normal human serum at 37°C for 0, 1, 2, 3, 6, 10 and 24 hours. For cathelicidin-BF, antimicrobial activities against *E. coli* 08A866 could not be detected after 3 h-incubation, while cathelicidin-BF15 could keep its antimicrobial activity up to 10 h in 90% fresh normal human serum. Cathelicidin-BF15 seems to be more stable than cathelicidin-BF in serum.

Discussion

Antimicrobial peptides (AMPs) and their precursor molecules form a central part of biological immunity. For the species which lack adaptive immunity, AMPs play a key role to defense microorganism infection. For their capacity to rapidly inactive infectious agents and to probably inhibit the emergence of drug resistance, AMPs have attracted considerable attention, especially for the treatment of antibiotic-resistant pathogens. The most two important AMP families, defensin and cathelicidin have been found in mammals, birds and fish. Coincidently, both defensin and cathelicidin have not been found in both reptiles and amphibians although a beta-defensin-like protein with unusual disulfide connectivity (C1-C6/C2-C5/C3-C4), which is different.
Table 1. Antimicrobial activity comparison of cathelicidin-BF with antibiotics.

<table>
<thead>
<tr>
<th>Microorganism strains</th>
<th>MIC (ug/ml)</th>
<th>BF</th>
<th>BF-15</th>
<th>Amp</th>
<th>Ben</th>
<th>ICS</th>
<th>HDW</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bacillus subtilis</td>
<td>9.4</td>
<td>75</td>
<td>0.02</td>
<td>0.004</td>
<td>-</td>
<td>2.3</td>
<td></td>
</tr>
<tr>
<td>Bacillus pumilis</td>
<td>9.4</td>
<td>-</td>
<td>0.15</td>
<td>0.015</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Bacillus cereus</td>
<td>1.2</td>
<td>-</td>
<td>150</td>
<td>150</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Pseudomonas aeruginosa</td>
<td>1.2</td>
<td>4.7</td>
<td>150</td>
<td>18.7</td>
<td>9.4</td>
<td>37.5</td>
<td></td>
</tr>
<tr>
<td>ATCC27853</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P. aeruginosa (IS, DR)</td>
<td>2.3</td>
<td>37.5</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>P. aeruginosa 08031205(IS, DR)</td>
<td>9.4</td>
<td>18.7</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>P. aeruginosa 08031014(IS, DR)</td>
<td>18.7</td>
<td>75</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>18.7</td>
<td></td>
</tr>
<tr>
<td>Escherichia coli ATCC25922</td>
<td>2.3</td>
<td>18.7</td>
<td>18.7</td>
<td>37.5</td>
<td>0.15</td>
<td>18.7</td>
<td></td>
</tr>
<tr>
<td>E. coli 08A852 (IS, DR)</td>
<td>1.2</td>
<td>18.7</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>E. coli 08A866(IS, DR)</td>
<td>0.6</td>
<td>18.7</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>18.7</td>
<td></td>
</tr>
<tr>
<td>E. coli 08031017 (IS, DR)</td>
<td>2.3</td>
<td>37.5</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>E. coli 08032813 (IS, DR)</td>
<td>2.3</td>
<td>&gt;100</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>E. coli 08040726 (IS, DR)</td>
<td>0.6</td>
<td>&gt;100</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>E. coli 08040722 (IS, DR)</td>
<td>0.6</td>
<td>9.4</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Staphylococcus aureus ATCC2592</td>
<td>4.7</td>
<td>75</td>
<td>0.15</td>
<td>0.03</td>
<td>-</td>
<td>1.2</td>
<td></td>
</tr>
<tr>
<td>S. aureus ATCC25923</td>
<td>&gt;400</td>
<td>ND</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>S. aureus 08A865 (IS, DR)</td>
<td>&gt;400</td>
<td>&gt;200</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>S. aureus 08A875 (IS, DR)</td>
<td>75</td>
<td>&gt;200</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>S. aureus 08031002 (IS, DR)</td>
<td>&gt;100</td>
<td>&gt;200</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>S. aureus 08031013 (IS, DR)</td>
<td>&gt;100</td>
<td>&gt;200</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>S. aureus 08032706 (IS, DR)</td>
<td>&gt;100</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>S. aureus 08032712 (IS, DR)</td>
<td>&gt;100</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>S. aureus 08032810 (IS, DR)</td>
<td>&gt;100</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acinetobacter calcoaceticus</td>
<td>2.3</td>
<td>-</td>
<td>75</td>
<td>37.5</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Sphingobacterium siiyangense</td>
<td>9.4</td>
<td>&gt;200</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Sacharbacillus kuerensis</td>
<td>4.7</td>
<td>4.7</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Serratia marcescens SA</td>
<td>&gt;400</td>
<td>&gt;200</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Serratia marcescens MA</td>
<td>&gt;400</td>
<td>&gt;200</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Pseudomonas luteola</td>
<td>1.2</td>
<td>200</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Salmonella typhi (IS, DR)</td>
<td>1.2</td>
<td>12</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Klebsiella pneumoniae (IS, DR)</td>
<td>4.7</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>K. pneumoniae 08031012 (IS, DR)</td>
<td>9.4</td>
<td>&gt;200</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>K. pneumoniae 08040202 (IS, DR)</td>
<td>0.6</td>
<td>75</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>K. pneumoniae 08040724 (IS, DR)</td>
<td>0.3</td>
<td>&gt;100</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Enterococcus faecium (IS, DR)</td>
<td>150</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Aspergillus terreus GIM3.34</td>
<td>18.7</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Aspergillus niger</td>
<td>18.7</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Chaetomium globosum</td>
<td>37.5</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Candida albicans ATCC2002</td>
<td>4.7</td>
<td>18.7</td>
<td>0.3</td>
<td>0.03</td>
<td>-</td>
<td>2.3</td>
<td></td>
</tr>
<tr>
<td>Pichia pastoris</td>
<td>0.3</td>
<td>9.4</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
</tbody>
</table>


doi:10.1371/journal.pone.0003217.t001

Table 2. Antimicrobial activity of cathelicidin BF in different solutions.

<table>
<thead>
<tr>
<th>Microorganism</th>
<th>MIC (ug/ml)</th>
<th>Water</th>
<th>150 mM NaCl</th>
<th>150 mM PBS</th>
</tr>
</thead>
<tbody>
<tr>
<td>E. coli ATCC25922</td>
<td>2.3</td>
<td>2.3</td>
<td>2.3</td>
<td></td>
</tr>
<tr>
<td>P. aeruginosa ATCC27853</td>
<td>1.2</td>
<td>0.6</td>
<td>0.6</td>
<td></td>
</tr>
<tr>
<td>S. aureus ATCC2592</td>
<td>4.7</td>
<td>2.4</td>
<td>2.4</td>
<td></td>
</tr>
<tr>
<td>C. albicans ATCC2002</td>
<td>4.7</td>
<td>2.4</td>
<td>2.4</td>
<td></td>
</tr>
</tbody>
</table>

MIC: minimal inhibitory concentration. These concentrations represent mean values of three independent experiments performed in duplicates. 

doi:10.1371/journal.pone.0003217.t002

Table 3. Bacterial killing kinetics of cathelicidin-BF against E. coli.

| Amount of bacteria co-cultured with different samples for different time (CFU) |
|---|---|---|---|---|---|
| Time (h) | 0 | 0.1 | 1 | 3 | 6 |
| Samples  | BFx1 | BFx5 | BFx10 | ICSx1 | ICSx5 |
| BFx1 | 50 | 0 | 0 | 0 | 0 |
| BFx5 | 50 | 0 | 0 | 0 | 0 |
| BFx10 | 50 | 0 | 0 | 0 | 0 |
| ICSx1 | 50 | 36 | 12 | 224 | 1082 |
| ICSx5 | 50 | 35 | 0.3 | 0.7 | 7 |
| 0.9% salt water | 50 | 45 | 234 | 2341 | 14109 |

BF: cathelicidin-BF, CFU: colony forming unit, ICS: Imipenem and Cilastatin Sodium for Injection, >1, >5 and >10: 1, 5 and 10 times, doi:10.1371/journal.pone.0003217.t003

Table 4. Bacterial killing kinetics of cathelicidin-BF and HDW against E. coli.

| Amount of bacteria co-cultured with different samples for different time (CFU) |
|---|---|---|---|---|---|
| Time (min) | 0 | 0.1 | 1 | 10 | 30 |
| Samples  | BFx1 | BFx5 | BFx10 | HDWx1 | HDWx10 |
| BFx1 | 50 | 32 | 0 | 0 | 0 |
| BFx5 | 50 | 20 | 0 | 0 | 0 |
| BFx10 | 50 | 10 | 0 | 0 | 0 |
| HDWx1 | 50 | 49 | 14.7 | 0 | 0 |
| HDWx10 | 50 | 38 | 3.7 | 0 | 0 |
| 0.9% salt water | 50 | 69 | 56 | 66.7 | 68.7 |

BF: cathelicidin-BF, CFU: colony forming unit, ×1, ×5 and ×10: 1, 5 and 10 times, HDW: A amphibian antimicrobial peptide from Rana nigrovittata. 

doi:10.1371/journal.pone.0003217.t004

from other the vertebrate beta-defensins, has been identified from a marine turtle [47,48]. Several hundreds of gene-encoded AMPs have been found from amphibians [12,39–42,49]. Only a few peptides or proteins from reptiles have been found to exert
antimicrobial activities, and most of them are phospholipases A₂ or its derivatives [34,50–52], and L-amino acid oxidase [53].

In the attempt to find AMPs from the snake venom of B. fasciatus, which is a rich source of biological peptides or proteins with therapeutic potential, an AMP, cathelicidin-BF, has been isolated and characterized. By screening the cDNA, cathelicidin-BF was unexpectedly found to be a C-terminus of a cathelicidin. The cathelicidin-BF precursor is composed of 191 amino acid residues with conserved cathelin domain that was flanked by signal peptide and by mature cathelicidin-BF. A conserved cleavage site (Valine¹⁵⁷) for elastase in the processing and maturation of bovine, porcine and chicken cathelicidins [30] is also existed in the cathelicidin-BF precursor, suggesting that the snake cathelicidin is possibly processed by elastase-like proteases. Based on the hypothesis, cathelicidin-BF precursor should release a 34-aa peptide fragment [KRFKKFKRLKKSVKKRAKEFFKKPR-VIGVSPF], which has a 4-aa (KRFK) extension at the N-terminus of the 30-aa cathelicidin-BF [KFRRKLKKSVKKRAKEFFKKPRVIGVSPF]. Two reasons may explain the length difference between the predicted 34-aa C-terminal peptide and the purified 30-aa cathelicidin-BF in this case: 1, the predicted cleavage site is right, and the purified 30-aa cathelicidin-BF is from the further processing of the 34-aa peptide; 2, Valine¹⁵⁷ in the cathelicidin-BF precursor is not the exact protease cleavage site. In fact, some cathelicidin is not cleaved by elastase to release C-terminal active peptide fragments as mentioned in this “introduction”. An obvious feather of cathelicidin-BF is that there is a high density (40%) of basic amino acid residues in its sequence. As some other cathelicidins [30], there are multiple aromatic amino acid residues in cathelicidin-BF’s sequence (5 Phenylalanines). An atypical feature of cathelicidin-BF precursor is that an acidic domain insertion (EEGQKQEGNEEKEVVEEEEEQED EKD) is located between the cathelin domain and the mature cathelicidin-BF. This region potentially could affect preproprotein net charge, stability, activity or processing. The similar acidic regions with conserved cathelin domain that was flanked by signal peptide domains and the mature antimicrobial domains [39–42]. Amphibian acidic regions act as a role to neutralize the positive charge of the mature antimicrobial domains and to avoid possible toxicity of the precursor proteins.

The data of antimicrobial testing indicated that cathelicidin-BF is clearly among the most potent cathelicidins discovered to date. Among the 40 strains of tested microorganisms, 15 strains could be killed by cathelicidin-BF at <0.6 μM. For a variety of microorganisms, cathelicidin-BF had better antimicrobial ability than ampicillin, benzylpenicillin and ICS. Cathelicidin-BF’s obvious ability to kill some saprophytic fungus such as A. terreus, A. niger and C. globosum is also very interesting. It may be used as agricultural antibiotics against plant or food pathogenic microorganisms. To our knowledge, this is the first report of cathelicidin’s antimicrobial activities against saprophytic fungus. In addition, cathelicidin-BF had very rapid microbe-killing efficacy. Cathelicidin-BF could kill E. coli within one minute at the dose of one time MIC. All the results suggest that cathelicidin-BF is an excellent candidate for clinical or agricultural antibiotics.

References

Supporting Information
Materials and Methods S1 Detail materials and methods
Found at: doi:10.1371/journal.pone.0003217.s001 (0.03 MB DOC)

Figure S1 Purification of the cathelicidin from snake venom. (a) Gel filtration chromatography. Sephadex G-50 column (2.6 cm×100 cm), equilibrated and developed with 50 mM Tris-HCl plus 50 mM NaCl (pH 7.8) at a flow rate of 0.3 ml/min, fractions were collected. (b) Cation-exchange chromatography. CM-Sephadex C-25 column (16 cm×40 cm) elution was achieved with a linear NaCl gradient, at a flow rate of 1 ml/min. (c) RP-HPLC chromatography. C4 reverse phase column, equilibrated with 0.1% (v/v) TFA/water, elution was performed with an acetonitrile liner gradient at a flow rate of 0.7 ml/min. The purified peptide with antimicrobial activity is indicated by an arrow.
Found at: doi:10.1371/journal.pone.0003217.s002 (0.17 MB TIF)

Figure S2 Electrospray ionization mass spectrometry analysis of the RP-HPLC peak containing antimicrobial activity. Found at: doi:10.1371/journal.pone.0003217.s003 (0.11 MB TIF)

Figure S3 Circular dichroism spectra recorded on cathelicidin-BF in different solvent environments. (A) a–c: in SDS micelles of 0, 30, 60, 90, 120 mM; (B) a–c: in TFE/H₂O mixtures of 1:9, 3:7, 5:5, 7:3, 9:1 (v/v).
Found at: doi:10.1371/journal.pone.0003217.s004 (0.13 MB TIF)

Figure S4 HN-HN regions of 2D ¹H-¹H NOESY spectra recorded on cathelicidin-BF in H₂O (left) and in TFE/H₂O mixture (9:1, v/v) (right).
Found at: doi:10.1371/journal.pone.0003217.s005 (0.12 MB TIF)

Figure S5 Hα CSI prediction for the cathelicidin-BF peptide in TFE/H₂O mixture (9:1, v/v): h: helix; c: coil.
Found at: doi:10.1371/journal.pone.0003217.s006 (0.16 MB TIF)

Figure S6 The opposing position of the hydrophilic and hydrophobic side chains can be seen in this end-on representation of the α-helix in the N-terminal region of cathelicidin-BF.
Found at: doi:10.1371/journal.pone.0003217.s007 (0.18 MB TIF)

Table S1 Contents of helical structures of cathelicidin in TFE/H₂O mixtures or in SDS micelles measured by CD.
Found at: doi:10.1371/journal.pone.0003217.s008 (0.03 MB DOC)

Table S2 ¹H chemical shifts of cathelicidin-BF in TFE/H₂O mixture (9:1, v/v) at 298 K
Found at: doi:10.1371/journal.pone.0003217.s009 (0.07 MB DOC)

Author Contributions
Conceived and designed the experiments: DL RL. Performed the experiments: YW JH XL HY RL JW AW. Analyzed the data: YW JH XL HY RL JW AW DL RL. Contributed reagents/materials/analysis tools: DL RL. Wrote the paper: YW JH XL DL RL.